(Q37399886)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

review article

1 reference

title

Recent advances in understanding and treating social anxiety disorder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Herman G M Westenberg

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

1 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

2 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

24-33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder

22 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Relation of shyness in grade school children to the genotype for the long form of the serotonin transporter promoter region polymorphism

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Reduced serotonin-1A receptor binding in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A complex relationship between co-occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Social phobia subtypes in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy of quetiapine in generalized social anxiety disorder: results from an open-label study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Anxiety disorders in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

The burden of social phobia in a Brazilian community and its relationship with socioeconomic circumstances, health status and use of health services: the Bambuí study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

https://api.crossref.org/works/10.1017%2FS1092852900027267

1 reference

7 January 2021

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Striatal function in generalized social phobia: a functional magnetic resonance imaging study.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Paroxetine in social anxiety disorder: a randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Paroxetine for social anxiety and alcohol use in dual-diagnosed patients

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Pharmacological treatment of social anxiety disorder: a meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy of olanzapine in social anxiety disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

An open trial of topiramate in the treatment of generalized social phobia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Increased amygdala activation to angry and contemptuous faces in generalized social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Increased activation of the anterior cingulate cortex during processing of disgust faces in individuals with social phobia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Low dopamine D(2) receptor binding potential in social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Duloxetine in the treatment of social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Size and burden of social phobia in Europe

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

An open-label trial of escitalopram in children and adolescents with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Treatment of social phobia with gabapentin: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

The Social Phobia and Anxiety Inventory: concurrent validity with a clinic sample

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Discontinuation of clonazepam in the treatment of social phobia.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Serotonergic intervention affects both social dominance and affiliative behaviour.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

An Open-Label Study of Levetiracetam for the Treatment of Social Anxiety Disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Facilitation of fear extinction by D-cycloserine: theoretical and clinical implications.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Lifetime co-morbidities between social phobia and mood disorders in the US National Comorbidity Survey

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A Comparison of the Efficacy of Clonazepam and Cognitive-Behavioral Group Therapy for the Treatment of Social Phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Social anxiety disorder and the risk of depression: a prospective community study of adolescents and young adults

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Sertraline for social phobia: a double-blind, placebo-controlled crossover study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Mirtazapine in social anxiety disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Association between anxiety disorders and substance use disorders among young persons: results of a 21-year longitudinal study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Dopamine reuptake site densities in patients with social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Citalopram treatment of social anxiety disorder with comorbid major depression

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Social anxiety disorder : current treatment recommendations

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Empirically supported psychological interventions for social phobia in adults: a qualitative review of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Acute SSRI administration affects the processing of social cues in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Tryptophan depletion reverses the therapeutic effect of selective serotonin reuptake inhibitors in social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Anterior cingulate neurochemistry in social anxiety disorder: 1H-MRS at 4 Tesla

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Treatment of social phobia with clonazepam and placebo.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: a meta-analysis of double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Placebo-controlled trial of moclobemide in social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Influence of the serotonin transporter promoter gene and shyness on children's cerebral responses to facial expressions

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

An eight-year longitudinal comparison of clinical course and characteristics of social phobia among men and women

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Augmentation of exposure therapy with D-cycloserine for social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Increased amygdala and insula activation during emotion processing in anxiety-prone subjects

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Tiagabine for social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

The relationship between anxiety and substance use disorders among individuals with severe affective disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Pharmacotherapy of Social Phobia

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Genome-wide linkage scan for loci predisposing to social phobia: evidence for a chromosome 16 risk locus

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study

1 reference

https://api.crossref.org/works/10.1017%2FS1092852900027267

7 January 2021

10.1017/S1092852900027267

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19238127%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference